

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
29 January 2004 (29.01.2004)

PCT

(10) International Publication Number
WO 2004/009088 A1

(51) International Patent Classification⁷: **A61K 31/506**,
A61P 35/00

(74) Agent: **GRUBB, Philip**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(21) International Application Number:
PCT/IB2003/001985

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(22) International Filing Date: 23 May 2003 (23.05.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/398,410 24 July 2002 (24.07.2002) US
60/454,557 14 March 2003 (14.03.2003) US

(84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.


(71) Applicant (*for all designated States except AT, US*): **NOVARTIS AG** [CH/CH]; Lichstrasse 35, CH-4056 Basel (CH).

(71) Applicant (*for AT only*): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(71) Applicants and

(72) Inventors: **OHTSURU, Akira** [JP/JP]; Yokoo 4-3-18, Nagasaki 852-8065 (JP). **PODTCHEKO, Alexej** [RU/JP]; Kokusaikouryuu- Kaikan, Sakamoto 1-7-1, Nagasaki 852-8523 (JP). **TSUDA, Satoshi** [JP/JP]; Hirano-machi 8-23, Nagasaki 852-8117 (JP). **YAMASHITA, Shunichi** [JP/JP]; Shiroyamadai 2-2-20, Nagasaki 852-8027 (JP).

(54) Title: 4-(4-METHYLPYPERAZIN-1-YLMETHYL)-N-[4-PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO)PHENYL]-BENZAMIDE FOR TREATING ANAPLASTIC THYROID CANCER



(I)

(57) Abstract: The invention relates to the use of 4-(4-methylpiperazin-1-ylmethyl)-N-[4 methyl-3-(4-pyridin-3yl)pyrimidin-2-ylamino)phenyl] benzamide of the following formula or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of anaplastic thyroid cancers.

WO 2004/009088 A1

INTERNATIONAL SEARCH REPORT

P B 03/01985

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K31/506 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, BIOSIS, MEDLINE, EMBASE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JOENSUU H ET AL: "TYROSINE KINASE INHIBITOR IMATINIB (STI571) AS AN ANTICANCER AGENT FOR SOLID TUMOURS" ANNALS OF MEDICINE, FINNISH MEDICAL SOCIETY DUODECIM, HELSINKI, FI, vol. 33, no. 7, 2001, pages 451-455, XP001131999 ISSN: 0785-3890 page 453, paragraph 2 --- --/--	1-8

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

16 September 2003

Date of mailing of the international search report

30/09/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Ludwig, G

INTERNATIONAL SEARCH REPORT

P B 03/01985

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>PODTCHEKO ALEXEI ET AL: "The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells."</p> <p>JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 88, no. 4, 20 April 2003 (2003-04-20), pages 1889-1896, XP009017078 ISSN: 0021-972X abstract</p>	1-8
P,X	<p>-----</p> <p>DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 20 December 2002 (2002-12-20) COHEN MARK S ET AL: "Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors." Database accession no. PREV200300111240 . XP002254691 abstract & SURGERY (ST LOUIS), vol. 132, no. 6, 20 December 2002 (2002-12-20), pages 960-967, ISSN: 0039-6060</p>	1-8
Y	<p>-----</p> <p>WO 99 03854 A (NOVARTIS ERFIND VERWALT GMBH ;NOVARTIS AG (CH); BUERGER HANS MICHA) 28 January 1999 (1999-01-28) page 3, paragraph 2; claim 1</p>	1-8
Y	<p>-----</p> <p>EP 0 546 409 A (BASF AG) 16 June 1993 (1993-06-16) . cited in the application page 4, line 1 page 16, line 27-29</p> <p>-----</p>	1-8

INTERNATIONAL SEARCH REPORT

P B 03/01985

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9903854	A	28-01-1999	AU 740713 B2	15-11-2001
			AU 8975998 A	10-02-1999
			BR 9810920 A	15-08-2000
			CN 1264375 T	23-08-2000
			WO 9903854 A1	28-01-1999
			EP 0998473 A1	10-05-2000
			HU 0003230 A2	28-06-2001
			JP 3276359 B2	22-04-2002
			JP 2001510192 T	31-07-2001
			NO 20000227 A	17-01-2000
			NZ 502295 A	21-12-2001
			PL 338129 A1	25-09-2000
			SK 432000 A3	12-06-2000
			TR 200000060 T2	21-09-2000
			TW 491845 B	21-06-2002
			US 2002115858 A1	22-08-2002
			ZA 9806362 A	22-01-1999
EP 0546409	A	16-06-1993	DE 4141219 A1	17-06-1993
			CA 2083654 A1	14-06-1993
			DE 59209536 D1	26-11-1998
			EP 0546409 A1	16-06-1993